Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001140361-18-005596
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2018-02-07 16:35:52
Reporting Period:
2018-01-30
Accepted Time:
2018-02-07 16:35:52
Original Submission Date:
2018-02-01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1322505 Albireo Pharma Inc. ALBO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1600023 Ltd Partners Phase4 1 Cavendish Place
London X0 W1G 0QF
No No No No
1687344 Phase4 Ventures Iii Lp 1 Cavendish Place
London X0 W1G 0QF
No No No No
1687418 Ltd Partner General Iii Ventures Phase4 50 Lothian Road, Festival Square
Edinburgh X0 EH3 9WJ
No No No No
1687429 Phase4 Ventures Iii Gp Lp 50 Lothian Road, Festival Square
Edinburgh X0 EH3 9WJ
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-01-30 98,500 $34.40 1,066,947 No 4 S Indirect Held by Phase4 Ventures III GP LP
Common Stock Disposition 2018-01-30 1,500 $37.06 1,065,447 No 4 S Indirect Held by Phase4 Ventures III GP LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Held by Phase4 Ventures III GP LP
No 4 S Indirect Held by Phase4 Ventures III GP LP
Footnotes
  1. The number of securities reported represents an aggregate number of shares sold in multiple market transactions over a range of sale prices. The Reporting Persons undertake to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Persons at each separate price within the range.
  2. Sale prices range from $34.40 to $34.71, inclusive.
  3. Sale prices range from $36.60 to $37.43, inclusive.
  4. Consists of shares held by Phase4 Ventures III GP LP ("Phase4 GPLP") in its capacity as general partner of Phase4 Ventures III LP ("Phase4 III"). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase 4 Ventures III General Partner Limited ("Phase4 GP"). Phase4 GP has appointed Phase4 Partners Limited ("Phase4 Partners") to act as the manager of Phase4 III. Dr. Alastair McKinnon, Denise Scots-Knight, PhD, and Charles Sermon are Directors of Phase4 Partners (the "Phase4 Directors"). Each of the Phase4 Directors, Phase4 Partners, Phase4 GP, Phase 4 GPLP and Phase4 III may be deemed to beneficially own the shares held by Phase4 GPLP in its capacity as general partner of Phase4 III, but disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.